...
首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.
【24h】

Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.

机译:质量控制可接受的实验室间变异对计算出的Fibrotest / Actitest分数的影响,用于肝纤维化的非侵入性生化评估。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Non-invasive, i.e. serum-based assessment of liver fibrosis is still an important diagnostic challenge although multiple single and multiparametric panels of biomarkers have been suggested. AIM: Two approaches were followed to determine the diagnostic reliability of Fibrotest and Actitest, two commercially distributed non-invasive multiparametric tests for staging and grading of liver fibrosis. METHODS: (i) Haptoglobin, ALT, gamma GT, alpha-2-macroglobulin, apolipoprotein A1 and bilirubin, required for calculation of respective scores, were determined in sera of 4 patients with histologically defined stages of fibrosis (F1-F4) and activities of fibrogenesis (A1-A3). Analytes were determined by 6 quality controlled external laboratories. Inter-laboratory variations of the calculated Fibrotest score for staging and Actitest score for grading (BioPredictive), and their error ratios referred to histologic results were calculated. (ii) The variability of respective Fibrotest/Actitest scores depending on 64 selected combinations of analytes within the accepted ranges of analyte-specific maximum/minimum limits given by the external quality control of the German Association of Clinical Chemistry and Laboratory Medicine (DGKL) was calculated. RESULTS: (i) Fibrotest and Actitest scores were largely reproducible among the different laboratories. However, the error ratio was 77% for all results calculated by both, Fibrotest and Actitest when referred to histologic findings. (ii) Calculated scores of stages varied between F2 (9%), F3 (31%), F3-F4 (6%), and F4 (54%) (Fibrotest), and A1/A2 (48%), A2 (9%), A2-A3 (5%), and A3 (38%) for grades of fibrogenic activity. CONCLUSION: Despite reproducibility of Fibro- and Actitest scores among the six laboratories, large scale investigation displayed high levels of variability depending on inter-laboratory differences that were still in a quality controlled, analytically acceptable range. Calculated scores coincided with histologic findings in less than 25% of all cases. Thus, the diagnostic accuracy of these tests must be considered as low, if histology is accepted as reference standard.
机译:简介:尽管已建议使用多个单一和多参数生物标志物,但非侵入性(即基于血清的肝纤维化评估)仍然是重要的诊断挑战。目的:采用两种方法来确定Fibrotest和Actitest的诊断可靠性,这两种用于商业化和分级肝纤维化的商业化非侵入性多参数测试。方法:(i)在4例具有组织学确定的纤维化分期(F1-F4)和活动的患者的血清中,确定计算各自分数所需的肝珠蛋白,ALT,γGT,α-2-巨球蛋白,载脂蛋白A1和胆红素纤维化(A1-A3)。分析物由6个质量控制的外部实验室确定。计算了分期的Fibrotest评分和分级的Actitest评分(BioPredictive)的实验室间变异及其相对于组织学结果的错误率。 (ii)相应的Fibrotest / Actitest分数的变异性取决于德国临床化学和实验室医学协会(DGKL)外部质量控制所给出的分析物特异性最大/最小限度的可接受范围内的64种选定分析物组合计算。结果:(i)Fibrotest和Actitest评分在不同实验室之间基本可重现。但是,当参考组织学发现时,由Fibrotest和Actitest计算出的所有结果的错误率均为77%。 (ii)阶段的计算分数在F2(9%),F3(31%),F3-F4(6%)和F4(54%)(Fibrotest)和A1 / A2(48%),A2( 9%),A2-A3(5%)和A3(38%)的纤维生成活性等级。结论:尽管六个实验室的Fibro-和Actitest评分具有可重复性,但大规模调查显示,根据实验室之间的差异,其可变性仍然很高,但仍处于质量控制且分析可接受的范围内。在所有病例中,计算出的分数与组织学结果相吻合的比例不到25%。因此,如果将组织学作为参考标准,则这些测试的诊断准确性必须被认为是低的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号